SCHEMBL22428552

SCHEMBL22428552

c1cncc(-c2cc(-c3cccc(-c4cccc(-c5ccncc5)c4)c3)cc(-c3cccc(-c4cccc(-c5ccncc5)c4)c3)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.62
CYP3A4 P08684 2/20 0.62
ALDH1A1 P00352 1/20 0.62
CYP1A2 P05177 1/20 0.62
MKNK1 Q9BUB5 3/20 0.60
MKNK2 Q9HBH9 3/20 0.60
MEN1 O00255 1/20 0.60
PSIP1 O75475 1/20 0.60
AXL P30530 1/20 0.60
CYP11B2 P19099 5/20 0.53
CYP11B1 P15538 4/20 0.53
CYP19A1 P11511 3/20 0.53
DYRK1A Q13627 1/20 0.53
DYRK1B Q9Y463 1/20 0.53
CYP17A1 P05093 1/20 0.53
KMO O15229 1/20 0.53
PIK3CA P42336 1/20 0.53
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24492814 1.00 CYP2A6 (0.62) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL16577179 1.00 CYP2A6 (0.62) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL22428539 1.00 CYP2A6 (0.62) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL17694301 1.00 CYP2A6 (0.62) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL19817613 0.98 CYP2A6 (0.65) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL18650155 0.96 CYP19A1 (0.59) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL24492856 0.96 CYP19A1 (0.59) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL18650154 0.96 CYP19A1 (0.59) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL12070033 0.96 CYP2A6 (0.68) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1
SCHEMBL12068188 0.96 CYP2A6 (0.68) CYP2A6CYP3A4ALDH1A1CYP1A2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177454-A1 TRISUBSTITUTED BENZENE COMPOUND HAVING NITROGEN-CONTAINING HETERO RING IN MOLECULAR TERMINUS AND ORGANIC ELECTROLUMINESCENCE ELEMENT HODOGAYA CHEMICAL CO., LTD. (JP) 2022-06-09 US disclosed
WO-2020184379-A1 TRISUBSTITUTED BENZENE COMPOUND HAVING NITROGEN-CONTAINING HETERO RING IN MOLECULAR TERMINUS AND ORGANIC ELECTROLUMINESCENCE ELEMENT 保土谷化学工業株式会社 2020-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177454-A1 TRISUBSTITUTED BENZENE COMPOUND HAVING NITROGEN-CONTAINING HETERO RING IN MOLECULAR TERMINUS AND ORGANIC ELECTROLUMINESCENCE ELEMENT ETV6, LEF1, TEAD2 CYP2A6 2586/4885CYP3A4 1434/4885ALDH1A1 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.